TABLE 1 Characteristics of Conjugate Pneumococcal Vaccines

Organization

Protein Carrier

Linker Technology

Saccharide Length

Vaccine Serotypes in Clinical Trials

Phase of Trials

Pasteur-Merieux Connaught

Tetanus toxoid Diphtheria toxoid

Short linker (new technology)

6, 14, 19, 23 (propose to add 3, 4, 9, and 18)

Phase I/II

Lederle-Praxis

CRM 197

Short linker

Short

6, 14, 18, 19, 23 (propose to add 4 and 9 for United States and 1 and 5 for “developing country” formulations)

Phase I/II

Merck

OMP-meningococcus B

Bivalent linker

Long

4, 6, 9, 14, 18, 19, 23

Phase I/II

University of Rochester

CRM 197, tetanus toxoid

Reductive amination

Short

6, 14, 19, 23 (amine)

Phase I

National Institute of Child Health and Human Development

Tetanus toxoid

Short linker (6-carbon)

Long

6, 12

Phase I

Dutch-Nordic Consortium

Tetanus toxoid

Thioether

Variable

None (propose to use a 4-valent vaccine similar to Merck’s)

None

SOURCE: National Institute of Allergy and Infectious Diseases, 1994.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement